@entity16949 for treatment of XXXX : efficacy, pharmacokinetics, hemodynamic effects and safety.

@entity1 @entity1165 @entity1540 @entity16949
Ten @entity1 were treated with oral @entity16949 for frequent @entity1540 during a short-term, dose-ranging, single blind inpatient trial followed by open label long-term therapy for 2 years. During dose ranging, @entity1 received placebo followed by 50, 75 and 100 mg of @entity16949 three times daily. Eight of the 10 @entity1 achieved greater than or equal to 80% reduction in @entity1540 during inpatient therapy. Mean @entity1540 decreased from 15,792/24 h to 2,357/24 h on optimal dosage (p less than 0.01). Nine @entity1 had paired @entity1540 ; four of the nine had greater than or equal to 99% reduction of these beats. Among seven @entity1 with nonsustained @entity1165 , five had 100% elimination of these events with @entity16949 and all had greater than or equal to 90% reduction in these events. @entity16949 prolonged the PR interval 44 +/- 27 ms (p less than 0.0001) and the QRS interval 11 +/- 9 ms (p less than 0.0001) from baseline without prolongation of the QTc or JTc interval. The mean trough plasma level of @entity16949 on optimal dosage was 409 +/- 173 ng/ml and the mean plasma elimination half-life was 10.3 +/- 2.3 h (range 7.1 to 14.2). No adverse hemodynamic effects of @entity16949 were detected. Side effects during short-term therapy were mild and did not require discontinuation of the drug. Efficacy was maintained for some @entity1 during long-term therapy for 2 years, although five @entity1 discontinued therapy because of loss of efficacy or side effects. @entity16949 is a highly effective and well tolerated antiarrhythmic drug for suppression of frequent and repetitive @entity1540 .
